Your browser doesn't support javascript.
loading
Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients.
Qu, Lihui; Lu, Yingying; Ying, Meike; Li, Bingjue; Weng, Chunhua; Xie, Zhoutao; Liang, Ludan; Lin, Chuan; Yang, Xian; Feng, Shi; Wang, Yucheng; Shen, Xiujin; Zhou, Qin; Chen, Ying; Chen, Zhimin; Wu, Jianyong; Lin, Weiqiang; Shen, Yi; Qin, Jing; Xu, Hang; Xu, Feng; Wang, Junwen; Chen, Jianghua; Jiang, Hong; Huang, Hongfeng.
Afiliação
  • Qu L; Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Lu Y; Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration Of Traditional Chinese Medicine Of PR China, Hangzhou, China.
  • Ying M; Key Laboratory Of Multiple Organ Transplantation, Ministry Of Health, Hangzhou, China.
  • Li B; Key Laboratory Of Nephropathy, Zhejiang Province, Hangzhou, China.
  • Weng C; Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Xie Z; Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration Of Traditional Chinese Medicine Of PR China, Hangzhou, China.
  • Liang L; Key Laboratory Of Multiple Organ Transplantation, Ministry Of Health, Hangzhou, China.
  • Lin C; Key Laboratory Of Nephropathy, Zhejiang Province, Hangzhou, China.
  • Yang X; Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Feng S; Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration Of Traditional Chinese Medicine Of PR China, Hangzhou, China.
  • Wang Y; Key Laboratory Of Multiple Organ Transplantation, Ministry Of Health, Hangzhou, China.
  • Shen X; Key Laboratory Of Nephropathy, Zhejiang Province, Hangzhou, China.
  • Zhou Q; Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Chen Y; Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration Of Traditional Chinese Medicine Of PR China, Hangzhou, China.
  • Chen Z; Key Laboratory Of Multiple Organ Transplantation, Ministry Of Health, Hangzhou, China.
  • Wu J; Key Laboratory Of Nephropathy, Zhejiang Province, Hangzhou, China.
  • Lin W; Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Shen Y; Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration Of Traditional Chinese Medicine Of PR China, Hangzhou, China.
  • Qin J; Key Laboratory Of Multiple Organ Transplantation, Ministry Of Health, Hangzhou, China.
  • Xu H; Key Laboratory Of Nephropathy, Zhejiang Province, Hangzhou, China.
  • Xu F; Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Wang J; Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration Of Traditional Chinese Medicine Of PR China, Hangzhou, China.
  • Chen J; Key Laboratory Of Multiple Organ Transplantation, Ministry Of Health, Hangzhou, China.
  • Jiang H; Key Laboratory Of Nephropathy, Zhejiang Province, Hangzhou, China.
  • Huang H; Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Oncotarget ; 8(46): 81285-81294, 2017 Oct 06.
Article em En | MEDLINE | ID: mdl-29113387
ABSTRACT
Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article